Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 4Completed 4Withdrawn 1Unknown 1Recruiting 1Not yet recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

OTHER 33INDUSTRY 4NIH 3UNKNOWN 2NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4Thoracic 2

Conditions

Neoplasms 1905Breast Neoplasms 1425Carcinoma, Non-Small-Cell Lung 1178Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 623Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Lymphoma 374Recurrence 373Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

osimertinib 1XL647 1AZD3759 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Meningeal Carcinomatosis × Clear all
NCT05146219 2024-12-30

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

TYK Medicines, Inc

Phase 2 Completed
29 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02228369 2021-01-05

BLOOM

AstraZeneca

Phase 1 Completed
108 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT00854867 2014-02-24

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Mundipharma Research Limited

Phase 1 Completed
18 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡